What's breaking now, across thousands of outlets.
Semi-annual redeterminations and work requirements will test payer-mix assumptions across the industry over the next two years. Now is the time for health systems to prepare, writes Ensemble SVP Matthew Ennen.
We haven't written up this one. Fierce Healthcare has the full story — the link below goes straight to it.
Judith Lucy's breast cancer diagnosis means she has joined a club nobody wants to be a part of. A survivor tells how humour and resilience can make the journey easier.
The latest news from CMS, HHS and more across Washington, D.C.
Curium has set the list price for Bexlutry, its radiosimilar to Novartis’ Lutathera, at $63,524 per infusion — about a 5% discount to the cost of the pharma giant’s drug.
(MedPage Today) -- After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.
Vaccination is one of the most important tools for preventing infectious diseases and protecting public health. However, immune responses after vaccination vary dramatically from person to person: If…
A study in Cameroon found that sickle cell trait is associated with distinct malaria parasite genotypes, potentially explaining reduced disease risk despite similar infection rates.
